Bonnie Bassler - Sanofi ADR Director
Director
Ms. Bonnie Bassler is Board Member of Sanofi SA. She graduated from University of California Davis with a degree in Biochemistry and obtained her Doctorate from John Hopkins University on Biochemistry. She is Member of the Narional Science Foundation and Board Member of American Association for the Advancement of Science. since 2014.
Tenure | 10 years |
Phone | 33 1 53 77 40 00 |
Web | https://www.sanofi.com |
Sanofi ADR Management Efficiency
The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0727 %, implying that it generated $0.0727 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities.The company has 18.42 B in debt with debt to equity (D/E) ratio of 0.3, which may show that the company is not taking advantage of profits from borrowing. Sanofi ADR has a current ratio of 1.27, demonstrating that it may have difficulties to pay its financial commitments when the payables are due. Debt can assist Sanofi ADR until it has trouble settling it off, either with new capital or with free cash flow. So, Sanofi ADR's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sanofi ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sanofi to invest in growth at high rates of return. When we think about Sanofi ADR's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Marc TessierLavigne | Regeneron Pharmaceuticals | 58 | |
Donald Denkhaus | Catalyst Pharmaceuticals | 72 | |
George Sing | Regeneron Pharmaceuticals | 68 | |
Fred Middleton | Chimerix | 67 | |
James Kern | Tscan Therapeutics | 49 | |
Philip Coelho | Catalyst Pharmaceuticals | 74 | |
Joseph Schepers | Chimerix | 58 | |
David Tierney | Catalyst Pharmaceuticals | 54 | |
Richard Goodrich | Chart Industries | 73 | |
Lisa Ricciardi | Chimerix | 57 | |
Admiral Giambastiani | Tscan Therapeutics | N/A | |
Nancy Hawthorne | Tscan Therapeutics | 66 | |
David Sagehorn | Chart Industries | 57 | |
Martha Demski | Chimerix | 65 | |
Michael Molinini | Chart Industries | 69 | |
Timothy Wollaeger | Chimerix | 68 | |
Ronald Renaud | Chimerix | 48 | |
Catherine Gilliss | Chimerix | 66 | |
Christine Poon | Regeneron Pharmaceuticals | 65 | |
Thomas Williams | Chart Industries | 59 | |
Anthony Coles | Regeneron Pharmaceuticals | 57 |
Management Performance
Return On Equity | 0.0727 | ||||
Return On Asset | 0.0454 |
Sanofi ADR Leadership Team
Elected by the shareholders, the Sanofi ADR's board of directors comprises two types of representatives: Sanofi ADR inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi ADR's management team and ensure that shareholders' interests are well served. Sanofi ADR's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi ADR's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee | ||
Emmanuel Babeau, Independent Director | ||
Roy Papatheodorou, Executive Counsel | ||
Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team | ||
Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee | ||
Dieter Weinand, Executive Vice President Member of the Executive Board | ||
Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team | ||
Eva SchaeferJansen, Head Relations | ||
Fabienne Lecorvaisier, Director | ||
George Grofik, Vice President of Investor Relations | ||
Karen Linehan, Executive VP of Legal Affairs and General Counsel | ||
Klaus Pohle, Independent Director | ||
John Reed, President - Global Research & Development, Member of the Executive Committee | ||
Bernard Charles, Independent Director | ||
Melanie Lee, Independent Director | ||
Madeleine Roach, Executive Operations | ||
Pierre Chancel, Senior Marketing | ||
Christophe Babule, Director | ||
Bonnie Bassler, Director | ||
Thomas Suedhof, Independent Director | ||
Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee | ||
Laurent Attal, Director | ||
JeanRene Fourtou, Independent Director | ||
JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee | ||
Josephine Fubara, Chief Care | ||
Christian Mulliez, Director | ||
Robert Castaigne, Independent Director | ||
Laurent Gilhodes, Principal Accounting | ||
Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team | ||
Uwe Bicker, Independent Director | ||
Josep Catlla, Head Communications | ||
Claudie Haignere, Independent Director | ||
Olivier Brandicourt, CEO, Director and Member of Strategy Committee | ||
Paul Hudson, CEO Director | ||
Bruno Mnard, Chief officer | ||
Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team | ||
Dante Beccaria, Global VP | ||
Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee | ||
William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee | ||
Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team | ||
David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe | ||
Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team | ||
Diane Souza, Independent Director | ||
Carole Piwnica, Independent Director | ||
Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team | ||
Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee | ||
Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team | ||
Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team | ||
DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee | ||
Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team | ||
Igor Landau, Director | ||
Patrick Kron, Independent Director | ||
Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee | ||
Gerard Kemmel, Independent Director | ||
SuetFern Lee, Independent Director | ||
Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team | ||
David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team | ||
Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee | ||
Suet Lee, Independent Director |
Sanofi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanofi ADR a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0727 | ||||
Return On Asset | 0.0454 | ||||
Profit Margin | 0.12 % | ||||
Operating Margin | 0.07 % | ||||
Current Valuation | 133.74 B | ||||
Shares Outstanding | 2.5 B | ||||
Shares Owned By Institutions | 9.94 % | ||||
Number Of Shares Shorted | 4.59 M | ||||
Price To Earning | 7.78 X | ||||
Price To Book | 1.54 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Tools for Sanofi Stock
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |